Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.
Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT’AIDS STUDY GROUP. Lions C, et al. Among authors: hocqueloux l. BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5. BMC Infect Dis. 2019. PMID: 30909885 Free PMC article.
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Castagna A, et al. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19. J Infect Dis. 2014. PMID: 24446523 Free PMC article. Clinical Trial.
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group. Fourati S, et al. J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3. J Antimicrob Chemother. 2015. PMID: 25558077 Free article.
Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group. Marcellin F, et al. Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25723557
Prevalence of and factors associated with depression among people living with HIV in France.
Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group. Feuillet P, et al. HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14. HIV Med. 2017. PMID: 27625202 Free article.
155 results